Takeda to execute planned acquisition of Adaptate Biotherapeutics

By The Science Advisory Board staff writers

January 11, 2022 -- Takeda Pharmaceutical announced it is exercising its option to acquire Adaptate Biotherapeutics. Takeda will obtain Adaptate's antibody-based variable delta 1 gamma delta T-cell engager platform, as well as its preclinical candidate and discovery pipeline programs.

The planned acquisition complements Takeda's ongoing efforts to research and develop cell engagers for solid tumor applications, bolstered by the novel T-cell engager Cobra platform, which was acquired from Maverick Therapeutics, Takeda said. The acquisition follows Takeda's recently exercised option to acquire GammaDelta Therapeutics.

Adaptate was formed in 2019 as a spinout company from GammaDelta, with investment from Abingworth and Takeda, in which Takeda received an exclusive right to purchase Adaptate for a prenegotiated upfront payment. The acquisitions of Adaptate and GammaDelta are expected to be finalized in the first quarter of Takeda's fiscal year 2022, pending review under applicable antitrust laws.

Financial details of the acquisition were not disclosed.


Copyright © 2022 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here